SBH
CLYM

Segall Bryant & Hamill’s Climb Bio CLYM Stock Holding History

Segall Bryant & Hamill’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-123,956
Closed -$223K – 644
2024
Q4 		$223K Buy
123,956
+65,545
+112% +$237K ﹤0.01% 574
2024
Q3 		$297K Buy
+58,411
New +$413K ﹤0.01% 558

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Segall Bryant & Hamill's CLYM Position: Q1 2025 in Review

Segall Bryant & Hamill sold out of Climb Bio (CLYM) in Q1 2025, closing a stake of 123,956 shares — an estimated $223K sold.

Segall Bryant & Hamill first reported a position in CLYM in Q3 2024 and held it in 2 quarters. The position peaked at $297K in Q3 2024. 76 funds tracked by Wall St. Rank hold CLYM as of Q1 2025.

  • Segall Bryant & Hamill reported no remaining Climb Bio position as of Q1 2025 after selling out during the quarter.
  • Segall Bryant & Hamill sold 123,956 Climb Bio shares in Q1 2025, an estimated $223K.
  • Segall Bryant & Hamill first reported a position in Climb Bio in Q3 2024 and held it in 2 quarters.
  • Segall Bryant & Hamill's Climb Bio position peaked at $297K in Q3 2024.
  • 76 funds tracked by Wall St. Rank held Climb Bio as of Q1 2025.

Based on Segall Bryant & Hamill's 13F filing for Q1 2025, filed 2 May 2025.